Gene therapy for prostate cancer targeting transcription factor E2F/DRTF

Area of Science:

• Molecular Biology
• Cancer Genetics
• Gene Therapy

Background:

• The E2F/DRTF transcription factor regulates genes essential for DNA replication and cell cycle progression.
• Prostate-specific antigen promoter (PSAP) offers tissue-specific gene expression for targeted therapies.
• Developing targeted prostate cancer therapies requires strategies to inhibit cancer cell proliferation specifically.

Purpose of the Study:

• To construct and evaluate prostate-specific gene therapy vectors targeting the E2F/DRTF pathway.
• To assess the efficacy of these vectors in inhibiting the growth of prostate cancer cell lines.
• To determine the tissue specificity of the gene therapy constructs.

Main Methods:

• Construction of three PSAP-driven plasmids (PSAP-E2FL, PSAP-E2FS, PSAP-antiE2F-1) to target E2F/DRTF via dominant-negative suppression and antisense mechanisms.
• Lipofection-mediated gene transfer into three prostate cancer cell lines (DU-145, PC-3, LNCaP) and six non-prostate cell lines.
• Assessment of cell growth inhibition, gene expression (RT-PCR), and DNA synthesis (BrdU incorporation).

Main Results:

• PSAP-E2FL, PSAP-E2FS, and PSAP-antiE2F-1 demonstrated significant, dose-dependent growth inhibition in prostate cancer cell lines DU-145, PC-3, and LNCaP.
• No significant growth inhibition was observed in hematopoietic, hepatic, renal, pulmonary, or colon cell lines, indicating high tissue specificity.
• PSAP-E2FL suppressed key oncogenes c-myc and DNA polymerase-alpha expression and inhibited DNA synthesis in DU-145 cells.

Conclusions:

• PSAP-driven genetic constructs targeting E2F/DRTF are effective in inducing prostate cancer cell-specific cytotoxicity.
• These constructs show potential for developing targeted gene therapies for prostate cancer with minimal off-target effects.
• The study highlights the feasibility of exploiting the E2F/DRTF pathway and PSAP promoter for tissue-specific cancer treatment.